1. ALLA AKTIER
  2. NYHETER
  3. ACOUSORT

AcouSort

Nyheter AcouSort Nyheter alla bolag

US cell therapy collaboration enters next level of evaluation

Earlier this year, AcouSort announced a rental deal of an AcouWash system to a US based cell therapy company. The first evaluation phase has generated very promising results, and the collaboration now enters the next phase with the order of evaluation kits at a total value of USD19,000.

The purpose of the rental deal initiated during late summer was for the partnering company to evaluate AcouSort’s technology for possible integration and automation of cell wash processes for cell therapy production. The next step in the project concerns interfacing and integrating AcouSort’s technology with the customers device testing how the technologies work together. The delivery of the evaluation kits is scheduled for Q1, 2025.

“We are very pleased to see this positive development and we are happy that our strategy to simplify access to our technology by providing test kits and instrument leases continues to pay off,” says Agnes Michanek, Commercial Director at AcouSort. “We are very much looking forward to seeing how this project will evolve in 2025.”

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments
US cell therapy collaboration enters next level of evaluation

Datum 2024-12-20, kl 10:00
Källa MFN
Bifogade filer
US cell therapy collaboration enters next level of evaluation
Affiliate
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.
Investeringar innebär en risk